HNHacker News
TopNewBestAskShowJobs

noname123

3,177 karma · joined August 14, 2009

submissionscomments
noname123··on Paternal stress in mice given to offspring via RNA packed into sperm
Hello, I don't have access nor the time to grok the full paper. http://www.pnas.org/content/early/2015/10/14/1508347112.full...

Can someone give a quick ELI5 into the exact method and rough biological explanation in the study?

From what I understand roughly from the artstechnica layman explanation, the microRNA expression can be influenced by an individual's environment (in the case of the mouse, 36 hours of constant light, a 15-minute exposure to fox odor etc.) These microRNA levels act somehow as regulators/promoters to chromosome molecular structure (basically whether a particular region is wound up tightly or loosely, making that region either harder or more accessible for the DNA transcription machinery), thereby effectively regulating the accessibility and expression of the genes (in this case, genes responsible for "down regulating stress [pathways] of mice") stored in that region.

Although the innate DNA structure (source code) didn't change from parent to offspring, the environment influences (Larmakian inheritance or metaphorically the user-defined environment path) was passed down to the offspring via the microRNA (that was optimized for/influenced by the father's environment) in the father's sperm cells - such that the genes are regulated epigenetically in the child same as the father's from the get-go (e.g., inheriting the environment paths, importing the older browser's bookmarks).

I have several questions, 1) please correct my layman understanding if any of it is off (don't have access to PNAS unfortunately), 2) if someone in the field can explain how microRNA actually regulate the chromosomes and histones, 3) Even if the microRNA is passed down to the offspring, is microRNA expression level in that offspring going to remain persistent? Meaning suppose the offspring is exposed to a totally different environment in contrast to the parent, will the offspring's microRNA eventually change to match its changing environment, i.e., how does microRNA get expressed and regulated in the first place?

Thanks for posting this very interesting paper on Larmakianism making a comeback!

noname123··on Biomedical superstars are signing on with Google
They have a collaboration with the Broad where they want to run their analysis pipeline on Google's compute cluster.

https://cloud.google.com/genomics/gatk?hl=en

They also have a project with Novartis (I think not with NIBR however) to do glucose testing via contact lenses.

http://www.reuters.com/article/2015/09/05/us-novartis-ceo-id...

If I have to guess, I don't think Google plan to build a HTS facility for drugs R&D or a huge lab foot-print to do wet-lab work. They probably want to leverage their existing compute/engineering infrastructure to get involved in the next phase of informatics needs in health care and life science (e.g., cloud storage and compute needs for clinical genome sequencing, analysis workflows like 23andMe for academia/industry/clinical).

noname123··on Biomedical superstars are signing on with Google
Different people, different strokes.

I got really bored working on e-commerce checkout funnels and A/B testing and constantly learning about new Javascript frameworks that churn out every year that does the same things over and over. With Coding Bootcamp churning out more CRUD people year by year, and JS frameworks and Agile automating web dev work to be like assembly-line; I found it to be both increasingly less financially secure and spiritually filling.

Genomics (for me personally) is more interesting; you get to learn a lot of statistics, biology and backend pipeline code. Also work environment in a lab is different, you have a lot more autonomy and you get to present your work and learn more about things in an academic/journal club/talks setting vs. the typical IT/Software Agile morning standup's. Not to mention the field is constantly changing, new sequencing technologies and new search algorithms are published constantly.

The salary for post-doc's is at that range. A research scientist or a software developer at least if you land at a well-funded place or BigPharma is about the same as a software developer (100-130K). I got out of the web-dev game a year ago; and I think while I am no longer on the cutting edge of the latest React.js/Node technology, I picked up new skills in concurrency, messaging system and machine learning (HMM, SVM, clustering etc) building whole genome annotation/analysis pipelines.

It has worked out for my personality but I have plenty of friends who get excited about doing new iOS and JS languages/frameworks so I respect that too (but not for me).

noname123··on The uncomfortable state of being Asian in tech
I don't necessarily think we need to have a discussion about being Asian in technology.

I appreciate how attractive a conversation can be and/or a Asian American forum or movement that discusses Asian American issues etc.

However, in my personal experiences, those conversations unfortunately don't go anywhere; mainly because we are not part of the protected class (nothing against under-represented minorities, I actually support affirmative action in tech and education; but Asians don't get the same advantages conferred unfortunately and it is futile and dishonest for us to try to get them IMHO).

Also like the author said, Asian experiences are very diverse. Priscilla Chan (Mark Zuckerburg's wife) for instance would have a very different experience than say a first-generation Chinese female software engineer working for Facebook (Asian American female issues, "Asian Fetish"; "Joy Luck Club" pressure from traditional parents to still toe the line of an filial daughter), and also a different experience to a 2nd-generation Korean male project manager (Asian American male issues, bamboo-ceiling, being perceived as a work-bee and docile in professional and social settings).

The most successful Asians I respect and try to learn from have dedication and commitment to a higher goal. I respect highly a short Vietnamese guy who have forgone a high-paying medical specialty to toil in pediatrics but he loves it; he also found love in a FOB plain jane but also loves her too. The pure joy and happiness he partakes in life is a refreshing contrast to other neurotic Asians I know in extremely high paying jobs and/or partaking in the yuppie urban lifestyle.

I think we can learn from and even internalize the spirit of the American civil rights leaders. But we have to "affect change" through our work and remain humble instead of "dialogue" and "forums" that sometimes turn into a narcissistic navel-gazing. I think ironically, the traditional Asian values are quite American, in the traditional self-effacing American puritans or the Mid-West kind of way that made this country great.

noname123··on Theranos Trouble: A First Person Account
Also somewhat tangential, but completely related, I'm curious peeps in biotech, what are your guys' opinions on Oxford Nanopore MinION?

IMHO, MinION is even more exciting than Theranos in that it is a real-time USB-stick sequencer that sequence a whole complete genome or the metagenomics inside a person's blood or guts (currently < 6hrs, in matters of minutes for detecting viral genomes in blood such as ebola since you can feed the sequencing data in a real-time pipeline to a BLAST to the viral genome reference database). Due to the early access program, there are quite a few papers published on its protocol attesting its pro's and con's.

Illumnia, the current king of genome sequencing has more its stock price than 10x since it has beaten out its NGS competitors as the "sequencer de-jure".

MinION, IMO like PacBio won't beat Illumina ever in read-error rate; however, can open up a new market in sequencing patient samples in clinical settings - which may be an order of magnitude bigger than academic sequencing. However, the argument against it is that there are already RT-PCR blood tests that can detect reliably in clinical settings different viral infections; also sequencing may be real-time, but you still need technicians to do the sample prep (e.g., extract the DNA and prep it for the NGS adapters).

Would love to hear people's opinions on the viability of nanopore sequencing here.

noname123··on Theranos Trouble: A First Person Account
> Considering that Holmes is on the Harvard Medical School Board of Fellows, while Church is one of its most prominent researchers, why is he suddenly speaking out?

I think Dr.Church's lab is very prominent in the field of synthetic biology; if I have to guess, his lab's work funding comes from lots of federal research grants outside of Harvard Medical school. So financially and politically, I don't think his hands are tied at all.

Also on principle, as a tenured faculty in academia, I don't think he is bound by the same rules/expectations as a FTE at a regular company.

noname123··on The War Over Genome Editing
From what I understand, the Broad patents are free to license for academic community and not free for industry.

https://www.broadinstitute.org/partnerships/office-strategic...

"Broad Institute, MIT, and Harvard University partners have made CRISPR-Cas9 technology broadly available to the research community. Broad Institute is working with AddGene, a non-profit plasmid repository, to offer Zhang lab CRISPR plasmids and reagents ... in addition we have non-exclusively licensed many industry partners for development of research tools and reagents and will continue to do so."

The reagent/CRISPR toolkit link here (can anyone just sign up and order the reagents?): https://www.addgene.org/CRISPR/

I'm curious, for peeps in industry who have licensed the original CRISPR/Cas9 patent from the Broad, what is the fee structure that the Broad is charging(?)

Or alternatively do people choose to license patents from the companies established by the three major PI's who claim discovery for different parts of CRISPR (Zhang, Doudna et al?)

Lastly, I'm curious why two 501(c) academic institutions are even fighting for this patent. Both UC Berkeley molecular biology dept. and Broad Institute are funded significantly via federal research grants that are awarded to individual labs within the organizations. If it seems like the status quo is that CRISPR is free to license for the academic community, does it matter which place owns the patent?

noname123··on [dead]
This. Completely agree.

Once I had a conversation with a female designer who organizes "Design hackathons" who said that she "gets disrespected on a regular basis" during meetup with "male participants." I actually agree with her on that point and can empathize with her.

However later on, she went on in a different context of conversation, to discount someone in her coding school program and justified how he is fast learner by his background: "he is just one of those computer nerds" and derided some job opportunities the group was discussing as some "stupid code monkey job".

IMHO, American society's left coast isn't progressive nor liberal but wants to feel progressive. I attended a extremely liberal and elite school in New England, and everyone on campus said the right things and some even did the right superficial things - but when it came to most sensitive things, dating/career/loyalty, everyone instinctively reverted back to the most base human tribal instinct.

In my early twenties, I used to feel upset and somewhat betrayed by my sullied idealism. But I got over it and realized that I am not special snowflake, and whatever difficulties, prejudices against me is nothing in context to other people's in history, better time could be used for me to learn and better myself (than sulking and railing with the "misery loves company" "social justice warrior"/"MRA"crowd on Facebook); and accumulate skills every day.

The same people who think a person is "just a 120lb nerd" or a "dumb jock" will be the same crowd that will "like" Facebook post about a "Science is Cool" post about a paper that the said nerd publishes later on, and likewise for the "jock"'s accomplishment dumbed down for the social media format. Hence people's need to "feel good," and need to not want to "feel bad" during the years it takes to be actually "good."

noname123··on Nassim Taleb's “Black Swan” Fund Made 1 Billion On Monday
Nassim Taleb buys options whose counterparty has multiple ways of hedging,

Suppose Taleb buys a put on SPX (S&P500 index) from an counter-party with a strike price of 1880, most prudent counter-party would re-hedge themselves by spending some of Taleb's premium to buy a cheaper SPX at a strike price of 1800.

Alternatively, the counterparty might put on dynamic hedge; meaning if SPX drops and it gets closer to Taleb's strike price, the Taleb counterparty will have to rush out and also short number of shares of SPX proportional to the option's pricing's sensitivity to the SPX, otherwise known as the delta of the option contract.

Suppose the counterparty didn't hedge properly or the market was super-volatile like this week Monday and counterparty didn't act fast enough to hedge and is brankrupt; then usually the counterparty's broker has to steps in (e.g., Charles Schwab or TDAmeritrade for retail investors or a huge investment bank's brokerage services for a hedge fund).

Suppose the trade is so huge that the broker defaults (e.g., when Swiss Franc de-pegged and blown up lots of retail forex accounts and forex brokers), each broker also has to go through a clearing broker who are the third-level of guarantor of the option contract; the two biggest one's for equity and options markets in US are Goldman Sachs Execution Services and Apex Clearing. Their sole job is to maintain a huge account of cash proportional to the trades they settle in case of settlement issues.

Now suppose the GSEC and Apex defaults also; then I'm not sure anymore, I'm guessing that the guarantee responsibility falls upon the charter members of the option or equity exchange - the burden of debt is distributed to the member of the exchange (brokers, banks). If all the exchange collective members go bankrupt, then I guess at that point, that means collecting your option payment would be your least problem...

noname123··on Cool Derivatives and Bank Consultants
Thanks jacksgavigan, I misread. Now I see the option positions that they're doing, I missed the fact that they are doing a bull-put spread and then a covered call.

Looks like they only make money on asset management fees and also commission fees; not on the spread of the option positions.

noname123··on Cool Derivatives and Bank Consultants
I trade options and was curious about the Vest startup: https://www.vestfin.com/

I think how they manage their risk is buy buying a covered call and put for their customers on the open market:

e.g.,

To replicate their SPY hedging strategy by Jan 15th 2016 here: https://www.vestfin.com/build-strategy/?symbol=SPY&preown=fa...

SPY is trading at 209.93;

"Select how much upside gain you are willing to cap at (235)", so sell a covered call at 235 that expires by 1/15/16; current options market: $0.04 credit

"Select how much downside risk you are willing to lose to (178)", so buy a put at 178 that expires by 1/15/16; current options market: $2.02 debit

Cost basis to implement via open market: $1.98/share

Cost basis to implement via Vest: $5.11/share

So their profit margin should be: $3.13/share or ~$300/option contract (account $13 for their commission and margin fees); now add their 0.5% management fee for the dollar value of this 100-lot SPY position (21504*0.005) or $107.52.

So the total profit they make per 1 SPY option contract is: $407.52!

And their active management involves only and only buying and selling these two option positions at the get-go!

If so, this is a pretty good business to get into!

Can someone else enlighten me if I did the math wrong here or I'm missing something here that I didn't account for their active management?

noname123··on The advantage high-frequency trading firms have over everyone else
I trade options spreads on orders of 2-week to month holding periods. So HFT isn't my specialty. But I'm trying to understand how latency arbitrage work, please let me know if this sounds about right.

(assuming all quotes at top of book is 100-lot).

at t = 0 ns

IWM quotes with NBBO of 120.10/120.15

BATS quotes IWM at spread of 120.10/120.15

ARCA quotes IWM at spread of 120.10/120.16

at t = 1 ns

Someone lowers their offer on ARCA, improving the spread on ARCA to 120.10/120.12*

Someone hikes their bid on BATS, improving the spread on BATS to 120.13*/120.16

Now according RegNMS, that improved ARCA offer should cross with the improved BATS bid and make a trade at 100 lot of IWM at 120.13. However, SIP lags by X ns; so either ARCA nor BATS route their customer's order externally for best price before X ns.

at t = a ns where a < X (where x is the SIP latency)

HFT co-located to BATS and ARCA detects this improved in price.

HFT bot takes the BATS bid, short IWM at 120.13, (position: -100 IWM; acct-cash: $12013)

HFT bot takes the ARCA offer, buys back IWM at 120.12, (position: 0 IWM; acct-cash: $1)

$1 revenue, and you do this a much of times a day and profit?

noname123··on Algorithmic Trading: The Play-at-Home Version
OK. Cool, I assume you trade either VIX put spreads or calendar spreads, or short VXX or long XIV on a VIX spike? If so, I do this as well. :)
noname123··on Algorithmic Trading: The Play-at-Home Version
Np, lifeisstillgood. I'm busy at work today, so am afraid I can't give full-length explanations. However I'll provide some links to some of the ideas.

HFT: Most HFT strategies involves making a market or rebate trading.

https://en.wikipedia.org/w/index.php?title=Market_maker&sect... https://en.wikipedia.org/wiki/Day_trading#Rebate_trading

They leverage being co-located next to the exchange servers and trading algorithmically. Anyone can sign up (provided you have >500K capital).

http://www.lightspeedinstitutional.com/automated-trading/lig... http://limebrokerage.com/SystematicTrading/Network/CoLocatio...

Algorithmic Trading: HFT is form of algo-trading, just higher frequency. Most peeps in the WSJ article is probably hooked up to Interactive Brokers via Quantopian doing swing trading (entering and exiting a position on order of days or weeks).

Here is a good Quantopian back test: https://www.quantopian.com/posts/system-based-on-easy-volati...

The paper behind the back test: http://www.naaim.org/wp-content/uploads/2013/00R_Easy%20Vola...

The gist is selling VXX, the VIX 30-day synthetic futures when a VIX ratio indicates that it is too overpriced. But should give you an idea of how a backtest works and how signal (VIX ratio) is generated.

Options Trading: It's harder to explain options satisfactorily in short space of time (basically you can google Black-Scholes model, options, option greeks). There's a whole online retail community devoted to this and probably very cultish and strange to people who don't follow it; but if you want to check it out: (https://www.tastytrade.com/tt/)

noname123··on Algorithmic Trading: The Play-at-Home Version
Interesting article but for a different take on a statistical approach to the market, curious if any peeps on HN are into volatility trading?

From what I understand a lot of the "DIY vendors" cater to the equity crowd, meaning people who build their models on technical indicators (MACD, RSI, advancers/decliners ratio, Fibonacci golden ratio retracement, MA); you build your model of some combined signals, back-test it with historical data on some tickers to see if it's promising.

I trade options, specifically selling 1.8-2 sigma calls and puts (with 90%-95% probability of not being in the money) on the major market indices (SPX, RUT, NDX) 45 days out from expirations; so kinda of like an insurance company underwriting policy or a bookie taking bets from both sides.

When the market moves against me (e.g., Grexit), I try to hedge my exposure to that side of the market by buying a longer dated call and put neutralizing the delta of my overall book (kind of like going to the re-insurance market to hedge my book); and also adjust the spread or close it entirely for a loss if risk/reward no longer works out.

But I never trade directional or have any market outlook; and do this systematically and only thing I change is sizing my book depending on how high VIX is (insurance premium/market fear).

This is a well-documented and traded strategy for peeps who follow, say TastyTrade, volatility arbitrage funds or just options in general. Just curious if anyone here also trades this way?

noname123··on Ask HN: Programmer Unions?
IMHO, if we are more united and concerned about our professions as a whole.

We'd organize to have professional licensing boards to artificially limit the supply of "licensed" coders and raise wages (e.g., American Medical Association that regulate MCAT/MLE Step exams, State Boards that administer bar exams etc, PE/professional engineer licenses).

But I'd like to consider coders as less calculating and more socialist that allows people from non-traditional backgrounds make the effort to join the ranks; and also heed to its "blue collar" technical roots than try to aspire to be elitist like doctors or lawyers.

noname123··on Silicon Valley is perhaps the most productive and innovative place in the world
lispm, I feel you bro. I used to get worked up about it but not as much anymore. The thing is, I see places like some places in startupland (e.g., HomeJoy, HubSpot) similar to Wharton. Meaning there's a higher concentration of self-centered and insecurely ambitious people who self-selectively go there to attempt to "make their bone". There are good people everywhere but the overall SV culture I personally want nothing to do with. So I'm happy for the "reverse social signaling" they give off and alternatively, imposing negative selection in the research cultural pool for people who are motivated purely by money.

I think there are plenty of people who are hard at work doing clean energy, climate protection etc. So I think the jury is still out in 10-15 years, whether a well-compensated mid-level Principal Engineer or Product Manager for "in-bound marketing" feels more satisfied than a Sr. Research Scientist in solar, environmental science etc. My bet is it is highly personal and contingent on the real impact the person made.

noname123··on China’s stock markets and revisiting 2011 predictions
Great article. I'm curious if peeps in North America are actively considering trading the situation in China.

What surprised me is when I looked into the implied volatility on FXI, the ETF for US market to look to trade large caps in China is only at 27%.

To put things in perspective, S&P500 Index implied volatility is at 10%. Google's IV is at 21%. Tesla Motors's IV is at 45%. Very weird when I expect the down-swings in China would put the IV at a much higher level.

So my thesis is that the IV on Chinese market is undervalued relative to SPY, buying a straddle on FXI (long vol in China) and selling a strangle/calendar on SPY IMO (short vol in US) is IMO a viable idea.

Curious if any peeps have any other ideas?

noname123··on A collaborative residency program in mathematical biology and deep learning
Thank you searine for your thoughtful and helpful reply to my post.

I will take your suggestion to "practice science" and follow up on the NCBI SRA website and look up some raw data upload; and see what piques my interest.

A readily available data source I see on NCBI is genetic surveillance project of Mycobacterium tuberculosis around the world.

There are three separate metagenomics/sequencing project of M. tuberculosis samples taken place in Japan, Nepal and Malawi. http://www.ncbi.nlm.nih.gov/Traces/sra/sra.cgi?view=studies&...

A very (vague) question I'd like to answer is: Are the SNPs identified in these separate geographical studies distinct or similar? Do different regions give way to distinct strains of TB? Do the metabolic pathways identified from these different strains of TB explain different viral adaptations to the host and its environment? I'm sure my posed questions are either already answered in literature, not posed properly and not feasible. But that'll be my starting point.

Much appreciated again!

noname123··on A collaborative residency program in mathematical biology and deep learning
Hi, I unfortunately cannot apply to a FT residency program as I have a FT job (as I suspect most people here do).

However, I do have an interest in Bioinformatics/Computational Biology. Unfortunately, I find that most textbooks that cover these topics are very theoretical, e.g., going over how Blast algorithm works, explanations of NGS assembly and annotation.

I'm curious any peeps in the field have any simple learning projects/practical papers for a programmer interested in Bioinformatics?

Things I'm thinking of are, (would like to hear from the experts any hints, tips or links):

1) Downloading a GWAS (Genome Wide Association) data-set for a psychiatric or cancer disease and replicating the statistical techniques that scientists used to determine the clusters of responsible genes (e.g., http://www.nature.com/nature/journal/v511/n7510/full/nature1...)

2) Downloading different strains of Cannabis Indica and Sativa genome draft assemblies; running initial phylenlogy tree and run genome annotation pipelines to identify known genes; and using RNASeq data to isolate the potencies of different varieties of Cannabis and metabolic pathways to produce hemp (e.g., http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3359589/)

3) Downloading data-set of RNASeq data from synthetic biology experiments involving yeast and replicating the statistical technique that authors used to determine the gene regulators/promoters used to program the cells to produce plastic, fuel and drugs for them! (http://www.nature.com/nature/journal/v440/n7086/full/nature0...)

noname123··on Why We Hurt Each Other: Tolstoy’s Letters to Gandhi
Tangential, I'm reading "War and Peace" right now for my book club, very difficult to slog through; just curious for peeps who've read either "War and Peace" or "Anna Karenina," what is so special about Tolstoy's novels, that makes it different than say their Western counterparts like say "Les Miserables" or "Pride and Prejudice"?
noname123··on The Art of Quitting
Totally I agree.

You can learn about coding on your own time anytime you want, at any age, on your own and with the help of free online courses, meetup's or paid courses etc.

Learning about M&A, building your professional network in investment banking, the financial markets is not so much accessible. Nothing against his enthusiasm/passion, I don't think OP was very wise to quit his job.

noname123··on Bay Area Doctors Quit Medicine to Work for Digital Health Startups
IMHO, a trained professional who can effectively diagnose and treat someone's medical condition, from something serious like cancer to minor like skin rash made a bigger difference in that person's life than someone who improved seconds off that person's "e-commerce checkout funnel" or delivered more "personal targeted ads" or even more improved "electronic medical patient records retrieval and storage" for that matter.
noname123··on NYSE/NYSE MKT has temporarily suspended trading in all symbols
Very interesting, obviously matters very little to retail traders as most retail brokerages either sell order-flow to marketmakers (e.g., Ameritrade) or have their own smart-router that looks at the liquidity of all exchanges/ECN and decides how to route their customers' orders (Interactive Brokers).

Quick question for trading peeps out there, is there a reason why one would want to direct orders directly to NYSE? Is it because it's still the place to trade bulk orders? (vs. say BATS or ARCA).

noname123··on Ask HN: Are you working on a Reddit replacement? What is it?
I want to put Arc to some serious load testing!

PG and current sys-admins of HN, open the flood gates, put in this ticket for HN development project: "Create sub-HackNewsies".

Also, I think Reddit source code is open source; so people can use that too! A great business idea I think is doing a bannedsubreddits.com/r/{banned}; crawl webarchive.org for the previous archives for all the banned subreddits for continuity...

noname123··on The Greatest Good: What is the best charitable cause in the world?
Can't believe, no one has posted this yet.

https://en.wikipedia.org/wiki/GiveWell

"GiveWell is an American non-profit charity evaluator and effective altruism-focused organization.[5][6] Unlike any other charity evaluators, GiveWell focuses primarily on the cost-effectiveness of the organizations that it evaluates, rather than traditional metrics such as the percentage of the organization's budget that is spent on overhead.[6][7] GiveWell recommends several charities per year. In 2014, its top recommendations were the Against Malaria Foundation, GiveDirectly, the Schistosomiasis Control Initiative, and the Deworm the World Initiative."

noname123··on Editing the Software of Life, for Fame and Fortune
Hi, I'm coming across CRISPR articles on a regular basis and was curious if any professional molecular biologist wet-lab peeps can give any pointers for DIY hobbyists if it's possible to do any DIY CRISPR experiments at any of the DIYBio hackerspaces around.

So I believe the CRISPR reagents/plasmids can ordered here: https://www.addgene.org/CRISPR/

A very rough guide for designing the experiment is shown here: https://www.addgene.org/crispr/planning-your-experiment/

I'm curious if it's possible for a layman to design a simple experiment say to 1) introduce the photoflourescent gene to bacteria via DNA recombinant techniques and 2) then maybe knock out that gene later via CRISPR by inserting some arbitrary nucleotides into the coding sequence of the photoflourescent gene, with visual confirmation; 3) and then re-enable photoflourescence later by deleting those arbitrary base-pairs with visual confirmation.

Would love to learn more and do some hands-on stuff since I'm hearing so much about CRISPR everyday!

noname123··on A high-frequency trading model using Interactive Brokers API in Python
Pretty cool stuff. Thanks for posting holoiii. Last year, I took some time off to build an IB API client in Java/Scala for options trading.

The biggest challenge I faced personally was dealing with concurrency of maintaining my positions, orders and quote ticks which led to orders as IB API is based on a asynchronous tick model. I ended up re-writing my code with lots of threads/locks to more code with immutability. Curious how you guys architected your IB client?

Also I hosted my client on the cloud on AWS. I subscribed to maybe a few symbols but always wondered in a more production environment whether bandwidth will kill you (subscribed to 100+ symbols and to a real tick-by-tick quote stream not quote snapshots).

Finally I'd love to hear more about folks out there who might be doing more options or futures trading off of IB API. The equity world is definitely very interesting but I found out early on that I enjoy trading delta-neutral and am not good at predicting directions.

Did you guys find that you have to scale up and write your own execution algo's when your size got too big for the market you are trading? Nowadays I use my IB client mostly as a GUI to view my positions and execute complex option spreads; so it's more of a "gray-box" for me. Do you guys trade pure algorithmically or half-and-half?

noname123··on Amazon, Google race to get human DNA into the cloud
Thanks eggie for your insight. Was wondering if you can give more specifics as to what you think are the challenges in going from a human genome assembly to drug discovery.
noname123··on Amazon, Google race to get human DNA into the cloud
I think there's been a lot of research/grants for working on population genetics; specifically, sequencing genomes and genetic expression profiles of patient pool of a particular disease (e.g., schizophrenia) and comparing it to the general population pool and clustering to find particular groups of genes that might be responsible for a particular disease.

Likewise, there are state agencies and startup's alike working on pre-natal genetics screening that basically tries to identify from pre-natal samples particular markers (SNPs) known for Down Syndrome, Tay-Sachs etc. Not to mention people who submit their samples to find interesting markers from 23andme.

I'd love to hear more from folks in the field what they think the next big application of computational biology, clinical genomics will be. Obviously, there has been a lot of mixed opinion regarding both on the consumer side (FDA banning 23andme from making broad statements of users having a higher-probability of cancer due to outdated and controversial data) and research side (has Human Genome Project since its completion in the early 2000's yielded a significant gene to target compound to drug on the market?)

More practically, Illumina (https://www.google.com/finance?q=NASDAQ%3AILMN&ei=af5xVYHoB4...) has more than 10x in the past 6 years, riding the wave of demand and growth of next-gen sequencing technology. If Cloud Computing is hailed as the sequencer's of the next phase in the biotech revolution, what stocks should I buy now to take advantage of it?

← PreviousPage 6 of 20Next →